{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "William Alden contributed reporting.", "original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Venture capitalist and Pharmacyclics chief executive Robert Duggan is selling publicly traded cancer drug company he rescued to drug maker AbbVie for $21 billion, but some analysts say company is not worth the price; AbbVie needs new popular drugs to sustain growth, however, and Pharmacyclics cancer drug Imbruvica could be just the ticket.", "type_of_material": "News", "word_count": "1225", "lead_paragraph": "Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much.", "pub_date": "2015-03-06T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "AbbVie Wins Bidding War for Maker of Cancer Drug, Then Goes on Defensive", "print_headline": "AbbVie Wins Bidding War, Then Goes on Defensive"}, "snippet": "Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much.", "multimedia": [{"height": 126, "url": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/03/06/business/DB-DRUG1/DB-DRUG1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/03/06/business/abbvie-wins-bidding-war-for-maker-of-cancer-drug-then-goes-on-defensive.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "AbbVie Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Pharmacyclics, Incorporated", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Duggan, Robert W", "name": "persons"}, {"rank": "5", "is_major": "Y", "value": "Cancer", "name": "subject"}], "blog": [], "_id": "54f90bd938f0d81f0d7a61ba", "source": "The New York Times"}